ScholarX

Browsing by Laribi, KamelAuthor

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Showing results 1 to 3 of 3

SCIESCOPUS
Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study

Yasenchak, Christopher; Kim, Jeong-A; Hahn, Uwe; Kim, Won-Seog; Fleury, Isabelle; Laribi, Kamel; Bergua Burgues, Juan Miguel; Bouabdallah, Krimo; Forward, Nicholas; Bijou, Fontanet, et al.

ArticleIssue Date2024CitationCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, v.24, pp S490 - S491PublisherCIG MEDIA GROUP, LP
SCIESCOPUS
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

Bartlett, Nancy L.; Hahn, Uwe; Kim, Won-Seog; Fleury, Isabelle; Laribi, Kamel; Bergua, Juan-Miguel; Bouabdallah, Krimo; Forward, Nicholas; Bijou, Fontanet; MacDonald, David, et al.

ArticleIssue Date2025CitationJournal of Clinical Oncology, v.43, no.9PublisherLippincott Williams and Wilkins
SCIESCOPUS
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study

Kim, Jeong A.; Hahn, Uwe; Kim, Won-Seog; Fleury, Isabelle; Laribi, Kamel; Burgues, Juan Miguel Bergua; Bouabdallah, Krimo; Forward, Nick; Bijou, Fontanet; MacDonald, David, et al.

ArticleIssue Date2024CitationJOURNAL OF CLINICAL ONCOLOGY, v.42, no.17_SUPPL, pp LBA7005 - LBA7005PublisherLIPPINCOTT WILLIAMS & WILKINS
1
STATISTICS
Total View:
Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어